Positive Asian Results Set Stage For Japan Perampanel Filing
This article was originally published in PharmAsia News
Executive Summary
Eisai has unveiled additional positive results for its novel anti-epileptic drug perampanel, this time from an Asian trial in refractory patients that will be used to support a planned Japanese approval filing.